Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE)

NASDAQ: PIE · Real-Time Price · USD
31.79
+0.10 (0.32%)
May 14, 2026, 4:00 PM EDT - Market closed
Assets$214.33M
Expense Ratio0.90%
PE Ratio23.07
Shares Outn/a
Dividend (ttm)$0.56
Dividend Yield1.75%
Ex-Dividend DateMar 23, 2026
Payout FrequencyQuarterly
Payout Ratio40.47%
Volume11,861
Open31.72
Previous Close31.69
Day's Range31.62 - 31.89
52-Week Low19.10
52-Week High32.30
Betan/a
Holdings114
Inception DateDec 28, 2007

About PIE

Fund Home Page

The Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) is an exchange-traded fund that mostly invests in total market equity. The fund tracks an index of stocks in emerging markets that show high relative strength characteristics. PIE was launched on Dec 28, 2007 and is issued by Invesco.

Asset Class Equity
Category Diversified Emerging Mkts
Region Global
Stock Exchange NASDAQ
Ticker Symbol PIE
ETF Provider Invesco
Index Tracked Dorsey Wright Emerging Markets Technical Leaders Index (Net)

Top 10 Holdings

26.99% of assets
NameSymbolWeight
Accton Technology Corporation23454.06%
Marketech International Corp.61963.15%
Sigurd Microelectronics Corporation62573.04%
Topco Scientific Co.,Ltd.54342.94%
Taiwan Semiconductor Manufacturing Company Limited23302.87%
United Integrated Services Co., Ltd.24042.68%
TISCO Financial Group PCL Units Non-Voting Depository ReceiptTISCO-R.BK2.19%
Yankey Engineering Co., Ltd.66912.09%
WinWay Technology Co., Ltd.65152.00%
Aselsan Elektronik Sanayi Ve Ticaret ASASELS.E.IS1.97%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Mar 23, 2026$0.02647Mar 27, 2026
Dec 22, 2025$0.24204Dec 26, 2025
Sep 22, 2025$0.08093Sep 26, 2025
Jun 23, 2025$0.20831Jun 27, 2025
Mar 24, 2025$0.00798Mar 28, 2025
Dec 23, 2024$0.03685Dec 27, 2024
Full Dividend History

Performance

PIE had a total return of 68.70% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.79%.

News

US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals

The U.S. ​Food and Drug Administration launched a pilot program on Monday aimed at allowing the ‌agency to monitor clinical trial data in real time, a step the agency said could cut years from drug ap...

Other symbols: IHEPPHXPH
16 days ago - Reuters